Comparative Pharmacology
Head-to-head clinical analysis: MEFOXIN versus MEFOXIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEFOXIN versus MEFOXIN IN PLASTIC CONTAINER.
MEFOXIN vs MEFOXIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking.
Cefoxitin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It is resistant to beta-lactamases produced by Gram-negative and Gram-positive bacteria.
1-2 g IV every 6-8 hours; usual dose 1 g IV every 6 hours for uncomplicated infections, 2 g IV every 6-8 hours for severe infections. Maximum 12 g/day.
1-2 g IV every 6-8 hours (adults).
None Documented
None Documented
Terminal elimination half-life 0.7-1.1 hours in normal renal function; prolonged to 5-9 hours in severe renal impairment (CrCl <10 mL/min)
0.7–1.2 hours in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily renal (85% unchanged) via glomerular filtration and tubular secretion; small biliary/fecal (<5%)
Primarily renal; 85% of a dose excreted unchanged in urine within 6 hours via glomerular filtration and tubular secretion. Biliary excretion accounts for <2%; fecal elimination minimal.
Category C
Category C
Cephamycin Antibiotic
Cephamycin Antibiotic